Dr. Debomita Chakraborty Ballowitz

PostDoc

Research interest include translational medicine and novel therapies in immune-oncology, inflammatory and fibrotic diseases. She obtained her PhD degree from the Medical Faculty of the Friedrich-Alexander University, Erlangen. Her PhD dissertation work focussed on the role of transcription factors in organ fibrosis and systemic sclerosis.  She worked as Post-Doc for a year in Erlangen before joining the lab of Dr. Krishnaraj Rajalingam in 2023. She will pursue her interests of identification of aberrant regulatory mechanisms, cell signalling pathways and molecular targets for developing therapeutic approaches towards cancer and inflammatory diseases.

Education

• 2023-present  Postdoctoral Researcher, at the University Medicine of the JGU Mainz

• 2022-2023      Postdoctoral Researcher at the University Hospital, Erlangen

• 2017-2022      PhD, medical faculty of the FAU Erlangen

• 2015-2017      scientific and research fellow, University Hospital Erlangen

• 2013-2015       Master of Technology in Agricultural and Pharmaceutical Biotechnology, IIT Kharagpur India with TU-Braunschweig (DAAD Scholarship)

• 2009-2013       Bachelor of Technology in Biotechnology from the Heritage Institute of Technology, WBUT, India

Publications

• Chakraborty, D., Romero, R., & Rajalingam, K. (2024). Integrate and conquer: pan-cancer proteogenomics uncovers cancer vulnerabilities and therapeutic opportunities. Signal Transduct Target Ther. 2024 Oct 15;9(1):289. doi: 10.1038/s41392-024-02009-6.

• Trinh-Minh, T., Chen, C. W., Tran Manh, C., Li, Y. N., Zhu, H., Zhou, X., Chakraborty, D., Zhang, Y., Rauber, S., Dees, C., Lin, N. Y., Kah, D., Gerum, R., Bergmann, C., Kreuter, A., Reuter, C., Groeber-Becker, F., Eckes, B., Distler, O., Fabry, B., … Distler, J. H. (2024). Noncanonical WNT5A controls the activation of latent TGF-β to drive fibroblast activation and tissue fibrosis. J Clin Invest. 2024 Mar 26;134(10):e159884. doi: 10.1172/JCI159884.

• Kechagioglou, P., Chakraborty, D., Dupont, C., Yurugi, H., Distler, U., Tenzer, S., ... Rajalingam, K. (2024). Narazaciclib’s differential targets and kinase inhibitory activity contribute to the enhanced inhibition of tumor growth in preclinical models [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO5-24-01.

• Dees, C., Chakraborty, D., & Distler, J. H. W. (2021). Cellular and molecular mechanisms in fibrosis. Exp Dermatol. 2021 Jan;30(1):121-131. doi: 10.1111/exd.14193.

• Bergmann, C., Hallenberger, L., Chenguiti Fakhouri, S., Merlevede, B., Brandt, A., Dees, C., Zhu, H., Zehender, A., Zhou, X., Schwab, A., Chen, C. W., Györfi, A. H., Matei, A. E., Chakraborty, D., Trinh-Minh, T., Rauber, S., Coras, R., Bozec, A., Kreuter, A., Ziemer, M., … Distler, J. H. W. (2021). X-linked inhibitor of apoptosis protein (XIAP) inhibition in systemic sclerosis (SSc). Ann Rheum Dis. 2021 Aug;80(8):1048-1056. doi: 10.1136/annrheumdis-2020-219822.

• Chakraborty, D., Zhu, H., Jüngel, A., Summa, L., Li, Y. N., Matei, A. E., Zhou, X., Huang, J., Trinh-Minh, T., Chen, C. W., Lafyatis, R., Dees, C., Bergmann, C., Soare, A., Luo, H., Ramming, A., Schett, G., Distler, O., & Distler, J. H. W. (2020). Fibroblast growth factor receptor 3 activates a network of profibrotic signaling pathways to promote fibrosis in systemic sclerosis. Sci Transl Med. 2020 Sep 30;12(563):eaaz5506. doi: 10.1126/scitranslmed.aaz5506.

• Chakraborty, D., Šumová, B., Mallano, T., Chen, C. W., Distler, A., Bergmann, C., Ludolph, I., Horch, R. E., Gelse, K., Ramming, A., Distler, O., Schett, G., Šenolt, L., & Distler, J. H. W. (2017). Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis. Nat Commun. 2017 Oct 24;8(1):1130. doi: 10.1038/s41467-017-01236-6. Erratum in: Nat Commun. 2021 Dec 8;12(1):7259. doi: 10.1038/s41467-021-27450-x.

•